Combined small cell lung carcinoma
Combined Small Cell Lung Carcinoma
Combined small cell lung carcinoma (C-SCLC) is a subtype of lung cancer characterized by the presence of both small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) components within the same tumor. This rare form of lung cancer presents unique challenges in diagnosis and treatment due to its mixed histological features.
Pathophysiology[edit | edit source]
C-SCLC arises from neuroendocrine cells in the lung and is distinguished by its aggressive behavior and rapid growth. The small cell component is typically composed of small, round, and densely packed cells with scant cytoplasm, while the non-small cell component can vary, often presenting as adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.
Diagnosis[edit | edit source]
Diagnosis of C-SCLC requires a thorough histopathological examination. A biopsy is performed to obtain tissue samples, which are then analyzed under a microscope. Immunohistochemical staining is often used to differentiate between the small cell and non-small cell components. Common markers include chromogranin A, synaptophysin, and CD56 for the small cell component, and TTF-1 and p40 for the non-small cell component.
Treatment[edit | edit source]
The treatment of C-SCLC is complex due to its dual nature. Standard treatment protocols for SCLC, such as chemotherapy with platinum-based agents and etoposide, are often employed. However, the presence of a non-small cell component may necessitate additional treatments, such as targeted therapy or immunotherapy, depending on the specific histological subtype and molecular characteristics.
Prognosis[edit | edit source]
The prognosis for patients with C-SCLC is generally poor, similar to that of pure SCLC, due to its aggressive nature and tendency for early metastasis. The presence of a non-small cell component does not significantly alter the overall prognosis, although it may influence treatment decisions.
Epidemiology[edit | edit source]
C-SCLC is a rare entity, accounting for a small percentage of all lung cancers. It is more common in smokers and typically presents in older adults. The exact incidence is difficult to determine due to variations in diagnostic criteria and reporting.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
